Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

​ Conditions: Ovarian Cancer

Interventions: Drug: INCB123667; Drug: Bevacizumab; Drug: Placebo

Sponsors: Incyte Corporation

Not yet recruiting Conditions: Ovarian Cancer
Interventions: Drug: INCB123667; Drug: Bevacizumab; Drug: Placebo
Sponsors: Incyte Corporation
Not yet recruiting